ASCO Chicago 2013: Inspired by the 2011 approval of ipilimumab the immunotherapy paradigm is experiencing a fervent revival in metastatic melanoma. Three novel strategies provoke the body’s immune system to attack melanomas are enabling patients to live better and longer with their disease. Read more.
Comments are closed.